dodecyl maltoside: Clinical Trials

5 trials of dodecyl maltoside, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 available, 1 completed, 1 recruiting. 2 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Recruiting 1
Phase 32Active not recruiting 2

Follow dodecyl maltoside: new trials by email Literature Review of dodecyl maltoside trials Research Report on dodecyl maltoside

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Phase 2RecruitingLepu Biopharma Co., Ltd.162025-12-042026-04-23
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, Urologic Cancer
Phase 3Active not recruitingCG Oncology, Inc.3672023-12-142026-07-01
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer
Phase 2CompletedCG Oncology, Inc.352020-12-082024-09-25
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Phase 3Active not recruitingCG Oncology, Inc.1902020-10-272026-07-10
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma
AvailableCG Oncology, Inc.2026-09-11

Conditions studied

Non-Muscle Invasive Bladder Neoplasms (5)  ·  Carcinoma in Situ (3)  ·  Carcinoma, Transitional Cell (2)  ·  Urinary Bladder Neoplasms (2)  ·  Urologic Neoplasms (2)

Sponsors

CG Oncology, Inc. (4)  ·  Lepu Biopharma Co., Ltd. (1)

Countries

United States (4)  ·  Canada (2)  ·  South Korea (2)  ·  Australia (1)  ·  China (1)  ·  Japan (1)  ·  Taiwan (1)

Top investigators

Max Kates, MD (1)

Results publications

PMID 38844794, PMID 42508433